NO20005295L - Effektiv rensing av adenovirus - Google Patents

Effektiv rensing av adenovirus

Info

Publication number
NO20005295L
NO20005295L NO20005295A NO20005295A NO20005295L NO 20005295 L NO20005295 L NO 20005295L NO 20005295 A NO20005295 A NO 20005295A NO 20005295 A NO20005295 A NO 20005295A NO 20005295 L NO20005295 L NO 20005295L
Authority
NO
Norway
Prior art keywords
adenovirus
solution
eluting
applying
sample solution
Prior art date
Application number
NO20005295A
Other languages
English (en)
Other versions
NO20005295D0 (no
Inventor
Miguel E Carrion
Marilyn Menger
Imre Kovesdi
Original Assignee
Genvec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec Inc filed Critical Genvec Inc
Publication of NO20005295D0 publication Critical patent/NO20005295D0/no
Publication of NO20005295L publication Critical patent/NO20005295L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
    • B01J41/20—Anion exchangers for chromatographic processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/06—Quantitative determination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N2030/621—Detectors specially adapted therefor signal-to-noise ratio
    • G01N2030/625—Detectors specially adapted therefor signal-to-noise ratio by measuring reference material, e.g. carrier without sample
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N30/06—Preparation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Dry Shavers And Clippers (AREA)

Abstract

Fremgangsmåte for å anrike en oppløsning av en adenovirus som omfatter å påføre en blandet oppløsning, som omfatter et adenovirus og minst en uønsket type biomolekyl, til en anionbytterkromatografiharpiks som inneholder en bindingsgruppe valgt fra grup- pen som består av dimetylaminopropyl, dimetylaminobutyl, dimetylaminoisobutyl og dimetylaminopentyl og eluere adenoviruset fra den kromatografiske harpiksen. Det tilveiebringes også en fremgangsmåte for å rense et adenovirus fra adenovirusinfiserte celler som omfatter å lysere slike celler, påføre lysatet til en enkelt kromatografisk har- piks, eluere adenoviruset fra kromatografiharpiksen og oppsamle en fraksjon som inne- holder adenovirus som hovedsakelig er så ren som trippei-CsCl-densitetsgradientrenset adenovirus. Foreliggende fremgangsmåte omfatter dessuten en fremgangsmåte for nøy- aktig å mengdebestemme antallet av adenoviruspartikler i en oppløsning av adenovirus som er karakterisert ved at man påfører til - og eluerer fra - en anionbytterkromatografi- harpiks en prøveoppløsning av adenovirus, sammenligner absorbansen- av prøveoppløs- - ningen av adenovirus og absorbansen av en standard adenovirus og mengdebestemmer antallet av adenoviruspartikler i prøveoppløsningen.
NO20005295A 1998-04-22 2000-10-20 Effektiv rensing av adenovirus NO20005295L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8262898P 1998-04-22 1998-04-22
PCT/US1999/008843 WO1999054441A1 (en) 1998-04-22 1999-04-22 Efficient purification of adenovirus

Publications (2)

Publication Number Publication Date
NO20005295D0 NO20005295D0 (no) 2000-10-20
NO20005295L true NO20005295L (no) 2000-11-30

Family

ID=22172352

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005295A NO20005295L (no) 1998-04-22 2000-10-20 Effektiv rensing av adenovirus

Country Status (20)

Country Link
US (3) US6383795B1 (no)
EP (1) EP1073721B1 (no)
JP (1) JP2002512361A (no)
AT (1) ATE303434T1 (no)
AU (1) AU756889B2 (no)
BG (1) BG104928A (no)
BR (1) BR9909789A (no)
CA (1) CA2328462C (no)
DE (1) DE69927013T2 (no)
EA (1) EA200001096A1 (no)
EE (1) EE200000605A (no)
HU (1) HUP0102209A2 (no)
IL (1) IL139040A0 (no)
IS (1) IS5673A (no)
MX (1) MXPA00010338A (no)
NO (1) NO20005295L (no)
PL (1) PL343630A1 (no)
SK (1) SK15682000A3 (no)
WO (1) WO1999054441A1 (no)
ZA (1) ZA200005363B (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
JP4492826B2 (ja) * 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
DE60029195T2 (de) 1999-02-22 2007-06-28 Transgene S.A. Verfahren zur Gewinnung von purifizierter Virenzusammensetzung
GB9915413D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Propagation method
US6447995B1 (en) 2000-10-04 2002-09-10 Genvec, Inc. Utilizing intrinsic fluorescence to detect adenovirus
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP3547715B2 (ja) * 2001-03-06 2004-07-28 榮 新垣 ベクター精製用装置及び方法
ES2564553T3 (es) * 2001-08-08 2016-03-23 The Trustees Of The University Of Pennsylvania Procedimiento para purificar vectores víricos que tienen proteínas que se unen a ácido siálico
EP1371723A1 (en) * 2002-06-12 2003-12-17 Procorde GmbH Process for preparing an adenovirus-containing preparation
EP1638587A4 (en) 2003-02-14 2007-04-18 Univ Missouri RECIPROCAL PROCEDURES AND COMPOSITIONS CONCERNING PROTEASOMAL INTERFERENCE
US20040166091A1 (en) * 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
AU2004249199B2 (en) * 2003-06-18 2008-07-24 Onyx Pharmaceuticals, Inc. Method for purifying virus
WO2005012537A2 (en) * 2003-07-25 2005-02-10 Genvec, Inc. Adenoviral vector-based vaccines
US8034643B2 (en) * 2003-09-19 2011-10-11 Tinggi Technologies Private Limited Method for fabrication of a semiconductor device
CA2545815A1 (en) * 2003-11-14 2005-06-09 Genvec, Inc. Adenoviral vectored tnf-a and chemoradiation to treat cancer
JP2007522814A (ja) * 2004-02-23 2007-08-16 クルセル ホランド ベー ヴェー ウイルスの精製方法
CN1972958B (zh) 2004-04-12 2013-01-23 美国政府卫生与公共服务部 应用腺病毒载体诱导免疫应答的方法
GB0411081D0 (en) * 2004-05-18 2004-06-23 Glaxo Group Ltd Novel apparatus
JP2008511336A (ja) * 2004-09-01 2008-04-17 アメリカ合衆国 免疫原性が増加したアデノウイルスベクターをインビボで用いる方法
AU2005305347A1 (en) * 2004-11-03 2006-05-18 Introgen Therapeutics Inc. Method of producing and purifying of adenoviral vectors
JP4626350B2 (ja) * 2005-03-22 2011-02-09 ソニー株式会社 ハイブリダイゼーション検出に適する反応部などを有する流路系、該流路系を用いるハイブリダイゼーション検出装置
SG10201912554TA (en) 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
DK1869171T4 (en) * 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
SI1912675T1 (sl) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
BRPI0618441B8 (pt) * 2005-11-10 2021-07-27 Genvec Inc vetor adenoviral
EP1808697A1 (en) * 2006-01-13 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Use of an ion exchange matrix for determining the concentration of virus particles and/or virus antigens
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
EP2167130A2 (en) * 2007-07-06 2010-03-31 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
EP2612867A1 (en) 2007-11-01 2013-07-10 Perseid Therapeutics LLC Immunosuppressive polypeptides and nucleic acids
SG189772A1 (en) * 2008-04-11 2013-05-31 Trubion Pharmaceuticals Inc Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
CN102203242B (zh) 2008-11-03 2013-06-12 克鲁塞尔荷兰公司 产生腺病毒载体的方法
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
EP2536829B1 (en) 2010-02-15 2016-04-06 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
MX362513B (es) 2010-03-23 2019-01-22 Intrexon Corp Vectores que expresan de manera condicional proteinas terapeuticas, celulas hospedadoras que comprenden vectores, y usos de los mismos.
SG10201600912SA (en) 2011-03-04 2016-03-30 Intrexon Corp Vectors conditionally expressing protein
CN102590431B (zh) * 2012-02-10 2014-04-02 济南康众医药科技开发有限公司 一种治疗咳嗽的中药药物组合物检测方法
IL292575A (en) 2014-09-07 2022-06-01 Selecta Biosciences Inc Methods and preparations for weakening immune responses by modulating gene expression in an antiviral transfer system
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
WO2018129268A1 (en) 2017-01-07 2018-07-12 Selecta Biosciences, Inc. Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
AU2018347583A1 (en) 2017-10-13 2020-05-21 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector IgM responses
GB201806736D0 (en) * 2018-04-25 2018-06-06 Ge Healthcare Bioprocess R&D Ab Method for virus purification
EP3927833A4 (en) 2019-02-21 2022-11-30 Unleash Immuno Oncolytics, Inc. ONCOLYTIC ADENOVIRAL VECTOR AND METHODS OF USE
CA3138525A1 (en) 2019-04-28 2020-11-05 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
AU2020284555A1 (en) 2019-05-28 2021-12-23 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
JP7698624B2 (ja) * 2019-07-12 2025-06-25 サンガモ セラピューティクス， インコーポレイテッド 空のおよび完全なウイルスキャプシド粒子の分離および定量化
CN118767143A (zh) 2019-12-12 2024-10-15 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4788223A (en) * 1985-07-26 1988-11-29 Rohm And Haas Company Low-rinse, high-capacity, weakly basic acrylic ion exchange resin
US5225989A (en) * 1988-05-19 1993-07-06 Fanuc Ltd. Apparatus and method for performing simultaneous control of control axes of a machine tool
US5228989A (en) 1989-07-06 1993-07-20 Perseptive Biosystems, Inc. Perfusive chromatography
US5019270A (en) 1989-07-06 1991-05-28 Perseptive Biosystems, Inc. Perfusive chromatography
AU654323B2 (en) * 1991-01-04 1994-11-03 Perseptive Biosystems, Inc. Sulfonamide bonded hydrophilic coating
US5268097A (en) 1992-06-19 1993-12-07 Sepracor Inc. Passivated and stabilized porous mineral oxide supports and method for the preparation and use of same
US5445732A (en) 1992-06-19 1995-08-29 Sepracor Inc. Passivated porous polymer supports and methods for the preparation and use of same
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
WO1997008298A1 (en) * 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
CA2184132C (en) * 1995-09-21 2011-03-15 Kristina J. Hennessy An adjuvanted vaccine which is substantially free of non-host albumin
JP2000514290A (ja) 1996-07-01 2000-10-31 ローヌ―プーラン・ロレ・エス・アー 組換えアデノウイルスの製造方法
JP4492826B2 (ja) * 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
CZ20012428A3 (cs) 1998-12-31 2001-11-14 Aventis Pharma S. A. Způsob separace virových částic
DE60029195T2 (de) 1999-02-22 2007-06-28 Transgene S.A. Verfahren zur Gewinnung von purifizierter Virenzusammensetzung

Also Published As

Publication number Publication date
EP1073721A1 (en) 2001-02-07
SK15682000A3 (sk) 2001-05-10
IS5673A (is) 2000-10-20
PL343630A1 (en) 2001-08-27
BG104928A (bg) 2001-09-28
HUP0102209A2 (hu) 2001-09-28
DE69927013T2 (de) 2006-06-29
EP1073721B1 (en) 2005-08-31
DE69927013D1 (de) 2005-10-06
BR9909789A (pt) 2000-12-26
WO1999054441A8 (en) 2000-02-24
CA2328462C (en) 2010-11-09
MXPA00010338A (es) 2005-06-17
ATE303434T1 (de) 2005-09-15
US20020034735A1 (en) 2002-03-21
NO20005295D0 (no) 2000-10-20
US20030203469A1 (en) 2003-10-30
AU756889B2 (en) 2003-01-23
CA2328462A1 (en) 1999-10-28
ZA200005363B (en) 2001-09-25
US6383795B1 (en) 2002-05-07
US6586226B2 (en) 2003-07-01
IL139040A0 (en) 2001-11-25
JP2002512361A (ja) 2002-04-23
EE200000605A (et) 2002-04-15
WO1999054441A1 (en) 1999-10-28
AU3662099A (en) 1999-11-08
US7141406B2 (en) 2006-11-28
EA200001096A1 (ru) 2001-04-23

Similar Documents

Publication Publication Date Title
NO20005295L (no) Effektiv rensing av adenovirus
Gotliv et al. Mollusk shell acidic proteins: in search of individual functions
Kirchman et al. The effect of amino acids on ammonium utilization and regeneration by heterotrophic bacteria in the subarctic Pacific
Clegg Glycoprotein detection in nitrocellulose transfers of electrophoretically separated protein mixtures using concanavalin A and peroxidase: application to arenavirus and flavivirus proteins
Carpinteiro et al. Applicability of solid-phase microextraction followed by on-fiber silylation for the determination of estrogens in water samples by gas chromatography–tandem mass spectrometry
DE3476276D1 (en) Assay method and kit for whole blood samples
CA2469815A1 (en) Methods for purifying protein
AU6236586A (en) Novel ligand-receptor assays employing squarate dyes
CA2246961A1 (en) Sample processing method using ion exchange resin
Van Egmond et al. Determination of mycotoxins
Shahtaheri et al. Development and optimisation of an immunoaffinity-based solid-phase extraction for chlortoluron
Staruszkiewicz Jr et al. Fluorometric determination of histamine in tuna: Development of method
US5618681A (en) Polyaromatic hydrocarbon (PAH) immunoassay method, its components and a kit for use in performing the same
Lombet et al. Ontogenic appearance of Na+ channels characterized as high affinity binding sites for tetrodotoxin during development of the rat nervous and skeletal muscle systems
Enegren et al. Chemical structure of attachment sites for viruses on human erythrocytes
Gomes et al. Reverse-phase high-performance liquid chromatography of chemically modified DNA
DK0789844T3 (da) Anvendelse af et BMP-proteinreceptor-kompleks til screening for aktive stoffer i knoglemetabolisme og celler, der er cotransficieret med en type II-BMP-receptor og en type I-BMP-receptor
CA2062820A1 (en) Monoclonal and polyclonal antibodies and test method for determination of fenitrothion and closely related organophosphates
Elliott et al. A rapid procedure for assaying nicotinamide phosphoribosyltransferase
WO2002038734A3 (en) Methods for determining the biological effects of compounds on gene expression
GB2223692A (en) Liquid chromatography
ES8305934A1 (es) "metodo para la determinacion de las proteinas glicosiladas presentes en fluidos biologicos".
Taylor et al. An automated procedure for the extraction and fluorimetric determination of 5-hydroxytryptamine in platelet subcellular fractions
WO1996013605A1 (en) A polyaromatic hydrocarbon (pah) immunoassay method, its components and a kit for use in performing the same
CA2271969A1 (en) Indicator means for liquid purification filter

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application